Investigation of the Tolerability of Two Facial Cleansing Routines for Mild to Moderate Acne

Sponsor
Northwestern University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05446402
Collaborator
(none)
50
1
1
18.5
2.7

Study Details

Study Description

Brief Summary

The objective of this study is to compare tolerability of two similar commercially available over the counter acne regimens (Geologie and Proactiv) in individuals with mild to moderate acne vulgaris over a 12-week daily treatment course.

Condition or Disease Intervention/Treatment Phase
  • Combination Product: Geologie Acne Regimen - one side of face
  • Combination Product: Proactive Acne Regimen - other side of face
Phase 4

Detailed Description

Acne vulgaris is a common, chronic inflammatory skin disorder that originates in the pilosebaceous unit. Acne typically begins in adolescence and often continues into adulthood, with about 20% of cases resulting in scars or hyperpigmentation. It's estimated that acne affects about 85% of adolescents. Individuals who experience acne and acne scars tend to also experience a negative impact on their social and mental health, including depression, anxiety, and social withdrawal. Currently, topical solutions and lifestyle changes are the primary treatment for mild to moderate acne.

This study will evaluate and compare the efficacy of two over the counter products in treating individuals with mild to moderate acne: Geologie and ProActive. Both sets of products will be provided to Northwestern in identical, unlabeled bottles for the purpose of blinding.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Participants will be using Product 1 regimen on left side of face for 12 weeks and Product 2 regimen on right side of face for 12 weeks.Participants will be using Product 1 regimen on left side of face for 12 weeks and Product 2 regimen on right side of face for 12 weeks.
Masking:
None (Open Label)
Masking Description:
All sets of products will be provided to Northwestern in identical, unlabeled bottles for the purpose of blinding.
Primary Purpose:
Treatment
Official Title:
Double Blinded, Split Face Investigation of the Tolerability of Two Facial Cleansing Routines for Mild to Moderate Acne
Actual Study Start Date :
Jun 15, 2022
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Acne Treatment

Combination Product: Geologie Acne Regimen - one side of face
Geologie is an over-the-counter cosmetic acne regimen with three products. The regimen also has three "levels" over the course of three months, in which the nighttime lotion is switched to a stronger formula each month. The Geologie Clear System regimen for acne prone skin includes: Clarifying Gel Cleanser - SA Formula (2% Salicylic Acid) Brightening Day Cream - SPF 15 (5% Azelaic Acid, 2% Hyaluronic Acid, 1%Niacinamide) Repairing Night Cream - Level 1 (0.05% Retinol, 3% Niacinamide, 2% Hyaluronic Acid) Level 2 (0.2% Retinol, 3% Niacinamide, 2% Hyaluronic Acid) Level 3 (0.3% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)

Combination Product: Proactive Acne Regimen - other side of face
ProActiv is an over-the-counter cosmetic regimen with three products. The Proactiv Solution 3-Piece System regimen includes: Renewing Cleanser (Active ingredient: 2.5% Benzoyl Peroxide) Revitalizing Toner (Glycolic Acid) Repairing Treatment (Active ingredient: 2.5% Benzoyl Peroxide)

Outcome Measures

Primary Outcome Measures

  1. Change in IGA Score between Geologie and ProActiv daily treatment [12 weeks]

    Investigator Global Assessment (IGA) will be collected on a scale of 0-4 with 0 being clear and 4 being severe.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 years or older

  • No known active skin infection.

  • Presence of mild or moderate acne on face (clinical diagnosis or self-report)

  • Willingness to give written consent and comply with study procedures.

Exclusion Criteria:
  • Active skin infection.

  • Inability to understand instructions or procedures involved.

  • Known allergy to ingredient(s) in products being used for study.

  • Pregnant women, prisoners, and vulnerable populations.

  • Has a history of acute or chronic disease that may interfere with or increase the risk of study participation.

  • Has any dermatological disorder that may interfere with the accurate evaluation of the subject's facial appearance, based on the opinion of the investigator.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Northwestern University Department of Dermatology Chicago Illinois United States 60611

Sponsors and Collaborators

  • Northwestern University

Investigators

  • Principal Investigator: Shuai Xu, Northwestern University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shuai (Steve) Xu, Principal Investigator, Northwestern University
ClinicalTrials.gov Identifier:
NCT05446402
Other Study ID Numbers:
  • STU#00217056
First Posted:
Jul 6, 2022
Last Update Posted:
Jul 11, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 11, 2022